vs
Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and WEST BANCORPORATION INC (WTBA). Click either name above to swap in a different company.
IRONWOOD PHARMACEUTICALS INC is the larger business by last-quarter revenue ($47.7M vs $26.9M, roughly 1.8× WEST BANCORPORATION INC). WEST BANCORPORATION INC runs the higher net margin — 39.2% vs -4.8%, a 44.0% gap on every dollar of revenue. On growth, WEST BANCORPORATION INC posted the faster year-over-year revenue change (16.6% vs -47.3%). IRONWOOD PHARMACEUTICALS INC produced more free cash flow last quarter ($74.6M vs $12.4M). Over the past eight quarters, WEST BANCORPORATION INC's revenue compounded faster (17.3% CAGR vs -20.2%).
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
West Bancorporation Inc. is a regional financial holding company headquartered in the U.S. Midwest, primarily serving markets across Iowa and Minnesota. It provides a full suite of personal and commercial banking services, including deposit accounts, mortgage loans, business lending, and wealth management solutions for individual consumers, small-to-medium enterprises, and local organizational clients.
IRWD vs WTBA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $47.7M | $26.9M |
| Net Profit | $-2.3M | $10.6M |
| Gross Margin | — | — |
| Operating Margin | 14.3% | 50.0% |
| Net Margin | -4.8% | 39.2% |
| Revenue YoY | -47.3% | 16.6% |
| Net Profit YoY | -200.9% | 34.8% |
| EPS (diluted) | $0.01 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $26.9M | ||
| Q4 25 | $47.7M | $24.2M | ||
| Q3 25 | $122.1M | $25.0M | ||
| Q2 25 | $85.2M | $23.8M | ||
| Q1 25 | $41.1M | $23.1M | ||
| Q4 24 | $90.5M | $20.9M | ||
| Q3 24 | $91.6M | $20.3M | ||
| Q2 24 | $94.4M | $19.6M |
| Q1 26 | — | $10.6M | ||
| Q4 25 | $-2.3M | $7.4M | ||
| Q3 25 | $40.1M | $9.3M | ||
| Q2 25 | $23.6M | $8.0M | ||
| Q1 25 | $-37.4M | $7.8M | ||
| Q4 24 | $2.3M | $7.1M | ||
| Q3 24 | $3.6M | $6.0M | ||
| Q2 24 | $-860.0K | $5.2M |
| Q1 26 | — | 50.0% | ||
| Q4 25 | 14.3% | 39.6% | ||
| Q3 25 | 61.8% | 45.8% | ||
| Q2 25 | 53.2% | 43.4% | ||
| Q1 25 | -70.7% | 43.4% | ||
| Q4 24 | 34.8% | 30.9% | ||
| Q3 24 | 28.0% | 36.6% | ||
| Q2 24 | 26.5% | 32.6% |
| Q1 26 | — | 39.2% | ||
| Q4 25 | -4.8% | 30.7% | ||
| Q3 25 | 32.8% | 37.3% | ||
| Q2 25 | 27.7% | 33.5% | ||
| Q1 25 | -90.9% | 34.0% | ||
| Q4 24 | 2.5% | 34.0% | ||
| Q3 24 | 4.0% | 29.3% | ||
| Q2 24 | -0.9% | 26.5% |
| Q1 26 | — | $0.61 | ||
| Q4 25 | $0.01 | $0.44 | ||
| Q3 25 | $0.23 | $0.55 | ||
| Q2 25 | $0.14 | $0.47 | ||
| Q1 25 | $-0.23 | $0.46 | ||
| Q4 24 | $0.03 | $0.41 | ||
| Q3 24 | $0.02 | $0.35 | ||
| Q2 24 | $-0.01 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $215.5M | $362.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-261.8M | $270.7M |
| Total Assets | $396.9M | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $362.0M | ||
| Q4 25 | $215.5M | $471.1M | ||
| Q3 25 | $140.4M | $232.9M | ||
| Q2 25 | $92.9M | $345.2M | ||
| Q1 25 | $108.5M | — | ||
| Q4 24 | $88.6M | $243.5M | ||
| Q3 24 | $88.2M | — | ||
| Q2 24 | $105.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $199.5M | — | ||
| Q2 25 | $199.3M | — | ||
| Q1 25 | $199.2M | — | ||
| Q4 24 | $199.0M | — | ||
| Q3 24 | $198.8M | — | ||
| Q2 24 | $198.6M | — |
| Q1 26 | — | $270.7M | ||
| Q4 25 | $-261.8M | $266.0M | ||
| Q3 25 | $-264.2M | $255.1M | ||
| Q2 25 | $-308.2M | $240.9M | ||
| Q1 25 | $-334.1M | $237.9M | ||
| Q4 24 | $-301.3M | $227.9M | ||
| Q3 24 | $-311.3M | $235.4M | ||
| Q2 24 | $-321.7M | $223.9M |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $396.9M | $4.1B | ||
| Q3 25 | $396.1M | $4.0B | ||
| Q2 25 | $342.9M | $4.1B | ||
| Q1 25 | $327.2M | $4.0B | ||
| Q4 24 | $350.9M | $4.0B | ||
| Q3 24 | $389.5M | $4.0B | ||
| Q2 24 | $395.6M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $74.6M | $12.9M |
| Free Cash FlowOCF − Capex | $74.6M | $12.4M |
| FCF MarginFCF / Revenue | 156.3% | 46.0% |
| Capex IntensityCapex / Revenue | 0.0% | 1.8% |
| Cash ConversionOCF / Net Profit | — | 1.22× |
| TTM Free Cash FlowTrailing 4 quarters | $127.0M | $79.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $12.9M | ||
| Q4 25 | $74.6M | $46.5M | ||
| Q3 25 | $47.6M | $11.4M | ||
| Q2 25 | $-15.1M | $13.5M | ||
| Q1 25 | $20.0M | $9.7M | ||
| Q4 24 | $15.2M | $39.8M | ||
| Q3 24 | $9.9M | $12.9M | ||
| Q2 24 | $33.5M | $10.0M |
| Q1 26 | — | $12.4M | ||
| Q4 25 | $74.6M | $43.2M | ||
| Q3 25 | $47.6M | $10.8M | ||
| Q2 25 | $-15.1M | $12.8M | ||
| Q1 25 | $19.9M | $8.3M | ||
| Q4 24 | — | $13.7M | ||
| Q3 24 | $9.9M | $7.0M | ||
| Q2 24 | $33.4M | $2.7M |
| Q1 26 | — | 46.0% | ||
| Q4 25 | 156.3% | 178.3% | ||
| Q3 25 | 39.0% | 43.0% | ||
| Q2 25 | -17.7% | 53.6% | ||
| Q1 25 | 48.4% | 35.7% | ||
| Q4 24 | — | 65.6% | ||
| Q3 24 | 10.8% | 34.2% | ||
| Q2 24 | 35.4% | 14.0% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 0.0% | 13.7% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 3.2% | ||
| Q1 25 | 0.1% | 6.5% | ||
| Q4 24 | 0.0% | 125.3% | ||
| Q3 24 | 0.0% | 29.4% | ||
| Q2 24 | 0.1% | 37.1% |
| Q1 26 | — | 1.22× | ||
| Q4 25 | — | 6.26× | ||
| Q3 25 | 1.19× | 1.23× | ||
| Q2 25 | -0.64× | 1.70× | ||
| Q1 25 | — | 1.24× | ||
| Q4 24 | 6.74× | 5.61× | ||
| Q3 24 | 2.71× | 2.17× | ||
| Q2 24 | — | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
